



PATENT APPLICATION  
File No: 00-25

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of : Darrell C. Conklin, Zeren Gao  
Serial No. : 09/819,136  
Group Art Unit : 1652  
Examiner : Ramirez, D.  
Filed : March 27, 2001  
For : MULTI-DOMAIN PROTEINASE INHIBITOR  
Date Submitted : December 14, 2001

**RECEIVED**

**JAN 30 2002**

**TECH CENTER 1600/2900**

**AMENDMENT FEE TRANSMITTAL**

BOX NON-FEE AMENDMENT  
Commissioner for Patents  
Washington, DC 20231

Sir:

Transmitted herewith is an Amendment for the above-mentioned application.

The fee required to be filed with the accompanying amendment has been calculated as shown below:


**CLAIMS AS AMENDED**

	<b>Claims Remaining After Amendment</b>	<b>Highest No. Covered by Previous Payments</b>	<b>Present Extra</b>	<b>Extra Rate</b>	<b>Fee</b>
Total	11	-25		\$9.00	\$000.00
Independent	4	-5		\$42.00	\$000.00
1st Presentation of Multiple Dependent Claim				\$140.00	\$000.00
<b>Total</b>					<b>\$000.00</b>

Applicants claim small entity status. Please charge any required fee to  
ZymoGenetics, Inc., Deposit Account No. 26-0290. A duplicate of this sheet is enclosed.

Respectfully submitted,

Gary E. Parker  
Registration No. 31,648



1652

PATENT APPLICATION

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: BOX NON-FEE AMENDMENT, Commissioner for Patents, Washington, D.C. 20231.

Dec. 14, 2001

Date

*Gary E. Parker*

Gary E. Parker

7/a  
S.93  
2/4/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

Applicants : Darrell C. Conklin, Zeren Gao  
Serial No. : 09/819,136  
Filed : March 27, 2001  
For : MULTI-DOMAIN PROTEINASE INHIBITOR

JAN 30 2002

TECH CENTER 1600/2900

Examiner : Ramirez, D.  
Art Unit : 1652  
Docket No. : 00-25  
Date : December 14, 2001

BOX NON-FEE AMENDMENT

Commissioner for Patents  
Washington, D.C. 20231

Response to Restriction Requirement and Preliminary Amendment

Sir:

Please amend the above-identified application as follows:

In the Claims:

Please cancel claims 9-22 and 25 without prejudice.

Please replace claims 23 and 24 with the following amended claims:

23. (amended) A protein produced by a method comprising the steps

of:

(a) culturing a cell comprising an expression vector comprising the following operably linked elements:  
a transcription promoter;

A1  
Rev C12